About this episode

Dr. Raza Bokhari discusses Medicus Pharma's promising Phase 2 results for SkinJect and future plans in oncology and rare diseases.

This interview is disseminated on behalf of Medicus Pharma Ltd. In this episode of Stocks to Watch, we are joined by Medicus Pharma (NASDAQ: MDCX) Executive Chairman and CEO Dr. Raza Bokhari to discuss the company's promising Phase 2 results for SkinJect, its innovative skin cancer treatment, and what lies ahead for the company across oncology, rare diseases, and prostate cancer. Learn more about Medicus Pharma: https://medicuspharma.com/ Watch the full YouTube interview here: https://youtu.be/4GZIBnS2KZ0 And follow us to stay updated: https://www.youtube.com/GlobalOneMedia

People in this episode

Guest: Dr. Raza Bokhari

Topics covered

• oncology
• skin cancer treatment
• rare diseases
• prostate cancer
• Phase 2 results

Keywords

• Medicus Pharma
• SkinJect

Mentioned in this episode

Organizations: Medicus Pharma Ltd., Medicus Pharma, NASDAQ

Products: SkinJect

More episodes of Stocks To Watch

• Episode 823: Aftermath Silver ($AAG | $AAGFF) CEO on Berenguela Project Drill Results and Next Steps · May 29, 2026 · 9 min
• Episode 822: Conexeu Sciences ($CNXU): The Future of Regenerative Aesthetics · May 27, 2026 · 25 min
• Episode 821: The FUTR Corporation CEO Discusses the Economic Opportunity Behind AI Banking and Consumer Data · May 21, 2026 · 17 min
• Episode 820: Don Durrett Shares His Checklist for Picking Mining Stocks · May 20, 2026 · 27 min
• Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease · May 19, 2026 · 14 min
• Episode 818: Planet Ventures Inc. ($PXI | $PNXPF): Breaking Barriers to Emerging Private Space Opportunities · May 19, 2026 · 11 min

Explore listener stats, chart rankings, contacts and more on the Stocks To Watch podcast page.